EAU 2014 - Poster: Cost-utility analysis of onabotulinumtoxinA vs best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Nick Freemantle,¹ Kristin Khalaf,² Daisy Ng-Mak,^2,* Clara Loveman,³ Sanja Stanisic,⁴ Dmitry Gultyaev,⁵ Johanna Lister,⁵ and Marcus Drake⁶ at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

¹Department of Primary Care and Population Health, UCL Medical School, London, United Kingdom; ²Allergan Inc., Irvine, CA, USA; ³Allergan Ltd, Marlow, United Kingdom; ⁴LA-SER ANALYTICA, Milan, Italy; ⁵LA-SER ANALYTICA, Lörrach, Germany; ⁶Department of Urology, Southmead Hospital, Bristol, United Kingdom *Currently Sunovion Pharmaceuticals Inc., Marlborough, MA, USA